help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on April 7, 2006, doi:10.1164/rccm.200512-1922OC

Am. J. Respir. Crit. Care Med., Volume 174, Number 1, July 2006, 84-93

A more recent version of this article appeared on July 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200512-1922OCv1
174/1/84    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christ-Crain, M.
Right arrow Articles by Muller, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christ-Crain, M.
Right arrow Articles by Muller, B.

Submitted on December 17, 2005
Accepted on April 6, 2006

Procalcitonin-Guidance of Antibiotic Therapy in Community-Acquired Pneumonia - A Randomized Trial

Mirjam Christ-Crain1*, Daiana Stolz2, Roland Bingisser3, Christian Muller4, David Miedinger2, Peter R Huber5, Werner Zimmerli6, Stephan Harbarth7, Michael Tamm2, and Beat Muller1

1 Department of Internal Medicine, University Hospital, Basel, Switzerland; Department of Endocrinology, University Hospital, Basel, Switzerland, 2 Department of Pneumology, University Hospital, Basel, Switzerland, 3 Department of Emergency Medicine, University Hospital, Basel, Switzerland, 4 Department of Internal Medicine, University Hospital, Basel, Switzerland, 5 Department of Clinical Chemistry, University Hospital, Basel, Switzerland, 6 Medical University Clinic, Kantonsspital, Liestal, Switzerland, 7 Division of Hospital Epidemiology, University Hospital, Geneva, Switzerland

* To whom correspondence should be addressed. E-mail: christmj{at}bluewin.ch.

Rationale: In patients with community-acquired pneumonia, guidelines recommend antibiotic treatment for 7 to 21 days. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications. Objective: To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia. Methods: In a randomized intervention trial, 302 consecutive patients with suspected community-acquired pneumonia were included. Data were assessed at baseline, at days 4, 6 and 8 and after 6 weeks. The control group (n=151) received antibiotics according to usual practice. In the procalcitonin group (n=151), antibiotic treatment was based on serum procalcitonin concentrations as follows: strongly discouraged <0.1µg/L; discouraged <0.25µg/L; encouraged >0.25µg/L; strongly encouraged >0.5µg/L. Primary endpoint was antibiotic use; secondary endpoints were measures of clinical, laboratory and radiographic outcome. Results: At baseline, both groups were similar with regards to clinical, laboratory and microbiology characteristics, and Pneumonia Severity Index (PSI). Procalcitonin-guidance reduced total antibiotic exposure (relative risk, 0.52; 95 % confidence interval [CI] 0.48-0.55; P<0.001), antibiotic prescriptions on admission (85 versus 99 %; P<0.001) and antibiotic treatment duration (median, 5 versus 12 days; P<0.001) compared to patients treated according to guidelines. After adjustment for PSI, the hazard ratio of antibiotic discontinuation was higher in the procalcitonin group than in the control group (3.2, 95 % CI 2.5 to 4.2). Outcome was similar in both groups with an overall success rate of 83 %. Conclusions: Procalcitonin-guidance substantially reduces antibiotic use in community-acquired pneumonia. These findings may have important clinical and public-health implications.
Key words: community-acquired pneumonia, antibiotic therapy, procalcitonin




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
M. Briel, P. Schuetz, B. Mueller, J. Young, U. Schild, C. Nusbaumer, P. Periat, H. C. Bucher, and M. Christ-Crain
Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care
Arch Intern Med, October 13, 2008; 168(18): 2000 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. N. Schwartz
Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care
Arch Intern Med, October 13, 2008; 168(18): 2007 - 2008.
[Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
M. Loebinger, A Shoemark, M Berry, M Kemp, and R Wilson
Procalcitonin in stable and unstable patients with bronchiectasis
Chronic Respiratory Disease, August 1, 2008; 5(3): 155 - 160.
[Abstract] [PDF]

Home page
 ThoraxHome page
S. Ewig and T. Welte
CRB-65 for the assessment of pneumonia severity: who could ask for more?
Thorax, August 1, 2008; 63(8): 665 - 666.
[Full Text] [PDF]

Home page
 ThoraxHome page
R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres
Markers of treatment failure in hospitalised community acquired pneumonia
Thorax, May 1, 2008; 63(5): 447 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2007
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. Nobre, S. Harbarth, J.-D. Graf, P. Rohner, and J. Pugin
Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic Patients: A Randomized Trial
Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 498 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Kruger, S. Ewig, R. Marre, J. Papassotiriou, K. Richter, H. von Baum, N. Suttorp, T. Welte, and on behalf of the CAPNETZ Study Group
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes
Eur. Respir. J., February 1, 2008; 31(2): 349 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Masia, J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez
Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia
Clin. Chem., December 1, 2007; 53(12): 2193 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Christ-Crain, D. Stolz, S. Jutla, O. Couppis, C. Muller, R. Bingisser, P. Schuetz, M. Tamm, R. Edwards, B. Muller, et al.
Free and Total Cortisol Levels as Predictors of Severity and Outcome in Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med., November 1, 2007; 176(9): 913 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Christ-Crain and B. Muller
Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators
Eur. Respir. J., September 1, 2007; 30(3): 556 - 573.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, A. Stulz, B. Muller, A. Gratwohl, and M. Tamm
BAL Neutrophils, Serum Procalcitonin, and C-Reactive Protein To Predict Bacterial Infection in the Immunocompromised Host
Chest, August 1, 2007; 132(2): 504 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. W. Arnold, J. T. Summersgill, A. S. LaJoie, P. Peyrani, T. J. Marrie, P. Rossi, F. Blasi, P. Fernandez, T. M. File Jr., J. Rello, et al.
A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 1086 - 1093.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. B. Milbrandt, A. Ishizaka, and D. C. Angus
Update in Critical Care 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 638 - 648.
[Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, C. Muller, J. Struck, B. Muller, and M. Tamm
Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD
Chest, April 1, 2007; 131(4): 1058 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. S. Niederman
Recent Advances in Community-Acquired Pneumonia: Inpatient and Outpatient
Chest, April 1, 2007; 131(4): 1205 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. J. Martinez and J. L. Curtis
Procalcitonin-Guided Antibiotic Therapy in COPD Exacerbations: Closer But Not Quite There
Chest, January 1, 2007; 131(1): 1 - 2.
[Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, M. Christ-Crain, R. Bingisser, J. Leuppi, D. Miedinger, C. Muller, P. Huber, B. Muller, and M. Tamm
Antibiotic Treatment of Exacerbations of COPD: A Randomized, Controlled Trial Comparing Procalcitonin-Guidance With Standard Therapy
Chest, January 1, 2007; 131(1): 9 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
Other articles noted
Evid. Based Med., December 1, 2006; 11(6): 191 - 192.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. P. Espana, A. Capelastegui, I. Gorordo, C. Esteban, M. Oribe, M. Ortega, A. Bilbao, and J. M. Quintana
Development and Validation of a Clinical Prediction Rule for Severe Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1249 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. Muller and M. Tamm
Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king.
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 848 - 849.
[Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
CAP: Guiding Therapy with Procalcitonin Levels?
Journal Watch Infectious Diseases, July 12, 2006; 2006(712): 6 - 6.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. G. Wunderink
A CAP on Antibiotic Duration.
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 3 - 5.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society 		  2009 ATS Conference Fees